Search Results - "Zibelman, Matthew"

Platinum-Free Systemic Therapy in First-Line Metastatic Urothelial Carcinoma: Mirage or Oasis in the Platinum Desert? by Plimack, Elizabeth R, Zibelman, Matthew R

“…Journal Journal of Clinical Oncology The systemic treatment for metastatic urothelial carcinoma has evolved over the past decade; however, changes in the…”
Get full text

Emerging role of immunotherapy in urothelial carcinoma—Advanced disease by Zibelman, Matthew, M.D, Ramamurthy, Chethan, M.D, Plimack, Elizabeth R., M.D., M.S

“…Abstract Systemic therapy for metastatic urothelial carcinoma has seen minimal progress and no new approved therapies in the past 20 years. However, with the…”
Get full text

Approved checkpoint inhibitors in bladder cancer: which drug should be used when? by Ghatalia, Pooja, Zibelman, Matthew, Geynisman, Daniel M., Plimack, Elizabeth

“…The treatment of advanced metastatic urothelial carcinoma has recently evolved with the approval of five checkpoint inhibitors. In the second-line setting, in…”
Get full text

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma by Zarrabi, Kevin K, Handorf, Elizabeth, Miron, Benjamin, Zibelman, Matthew R, Anari, Fern, Ghatalia, Pooja, Plimack, Elizabeth R, Geynisman, Daniel M

“…Treatment of metastatic renal cell carcinoma (mRCC) is rapidly evolving with new combination therapies demonstrating improved response rates and survival…”
Get full text

Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216) by Agarwal, Neeraj, Tangen, Catherine M, Hussain, Maha H A, Gupta, Shilpa, Plets, Melissa, Lara, Primo N, Harzstark, Andrea L, Twardowski, Przemyslaw W, Paller, Channing J, Zylla, Dylan, Zibelman, Matthew R, Levine, Ellis, Roth, Bruce J, Goldkorn, Amir, Vaena, Daniel A, Kohli, Manish, Crispino, Tony, Vogelzang, Nicholas J, Thompson, Jr, Ian M, Quinn, David I

“…Orteronel (TAK-700) is a nonsteroidal 17,20-lyase inhibitor suppressing androgen synthesis. We evaluated the clinical benefit of orteronel when added to…”
Get full text

The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Real-World Multi-Institutional Analysis by Ghatalia, Pooja, Handorf, Elizabeth A, Geynisman, Daniel M, Deng, Mengying, Zibelman, Matthew R, Abbosh, Philip, Anari, Fern, Greenberg, Richard E, Viterbo, Rosalia, Chen, David, Smaldone, Marc C, Kutikov, Alexander, Uzzo, Robert G

“…The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) was challenged by the results of the CARMENA trial. Here we evaluate the…”
Get full text

Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma by Gulati, Shuchi, Barata, Pedro C, Elliott, Andrew, Bilen, Mehmet Asim, Burgess, Earle F, Choueiri, Toni K, Darabi, Sourat, Dawson, Nancy Ann, Gartrell, Benjamin Adam, Hammers, Hans J, Heath, Elisabeth I, Magee, Daniel, Rao, Arpit, Ryan, Charles J, Twardowski, Przemyslaw, Wei, Shuanzeng, Brugarolas, James, Zhang, Tian, Zibelman, Matthew R, Nabhan, Chadi, McKay, Rana R

“…BACKGROUNDMetastases are the hallmark of lethal cancer, though underlying mechanisms that drive metastatic spread to specific organs remain poorly understood…”
Get full text

Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors by Miron, Benjamin, Handorf, Elizabeth, Zarrabi, Kevin, Zibelman, Matthew R., Anari, Fern, Ghatalia, Pooja, Plimack, Elizabeth R., Geynisman, Daniel M.

“…BACKGROUNDThe therapeutic landscape for advanced urothelial carcinoma (mUC) has changed significantly since studies establishing superiority of cisplatin as…”
Get full text

Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma by Ghatalia, Pooja, Zibelman, Matthew, Geynisman, Daniel M., Plimack, Elizabeth R.

“…Opinion statement The advent of checkpoint inhibitors has revolutionized systemic therapy for many malignancies, including renal cell carcinoma (RCC) where…”
Get full text

A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy by Jang, H Josh, Hostetter, Galen, Macfarlane, Alexander W, Madaj, Zachary, Ross, Eric A, Hinoue, Toshinori, Kulchycki, Justin R, Burgos, Ryan S, Tafseer, Mahvish, Alpaugh, R Katherine, Schwebel, Candice L, Kokate, Rutika, Geynisman, Daniel M, Zibelman, Matthew R, Ghatalia, Pooja, Nichols, Peter W, Chung, Woonbok, Madzo, Jozef, Hahn, Noah M, Quinn, David I, Issa, Jean-Pierre J, Topper, Michael J, Baylin, Stephen B, Shen, Hui, Campbell, Kerry S, Jones, Peter A, Plimack, Elizabeth R

“…On the basis of preclinical evidence of epigenetic contribution to sensitivity and resistance to immune checkpoint inhibitors (ICI), we hypothesized that…”
Get full text

Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles by Barata, Pedro, Gulati, Shuchi, Elliott, Andrew, Hammers, Hans J, Burgess, Earle F, Gartrell, Benjamin A, Darabi, Sourat, Bilen, Mehmet A, Basu, Arnab, Geynisman, Daniel M, Dawson, Nancy A, Zibelman, Matthew R, Zhang, Tian, Wei, Shuanzeng, Ryan, Charles J, Heath, Elisabeth I, Poorman, Kelsey A, Nabhan, Chadi, McKay, Rana R

“…Molecular profiling of clear cell RCC (ccRCC) tumors of clinical trial patients has identified distinct transcriptomic signatures with predictive value, yet…”
Get full text

Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin‐Based Chemotherapy for Muscle‐Invasive Bladder Cancer by Osterman, Chelsea K., Babu, Dilip S., Geynisman, Daniel M., Lewis, Bianca, Somer, Robert A., Balar, Arjun V., Zibelman, Matthew R., Guancial, Elizabeth A., Antinori, Gianna, Yu, Shun, Narayan, Vivek, Guzzo, Thomas J., Plimack, Elizabeth R., Vaughn, David J., Fung, Chunkit, Mamtani, Ronac

“…Neoadjuvant cisplatin‐based chemotherapy (NAC; 70 mg/m2) is standard of care for muscle‐invasive bladder carcinoma (MIBC). Many patients (pts) cannot receive…”
Get full text

A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors by Zibelman, Matthew, MacFarlane, Alexander W., Costello, Kimberly, McGowan, Thomas, O’Neill, John, Kokate, Rutika, Borghaei, Hossein, Denlinger, Crystal S., Dotan, Efrat, Geynisman, Daniel M., Jain, Angela, Martin, Lainie, Obeid, Elias, Devarajan, Karthik, Ruth, Karen, Alpaugh, R. Katherine, Dulaimi, Essel Al-Saleem, Cukierman, Edna, Einarson, Margret, Campbell, Kerry S., Plimack, Elizabeth R.

“…This phase I, dose-escalation trial evaluates the safety of combining interferon-gamma (IFN-γ) and nivolumab in patients with metastatic solid tumors…”
Get full text

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden by Morrison, Carl, Pabla, Sarabjot, Conroy, Jeffrey M, Nesline, Mary K, Glenn, Sean T, Dressman, Devin, Papanicolau-Sengos, Antonios, Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Qin, Moachun, Wang, Yirong, Lenzo, Felicia L, Omilian, Angela, Bshara, Wiam, Zibelman, Matthew, Ghatalia, Pooja, Dragnev, Konstantin, Shirai, Keisuke, Madden, Katherine G, Tafe, Laura J, Shah, Neel, Kasuganti, Deepa, de la Cruz-Merino, Luis, Araujo, Isabel, Saenger, Yvonne, Bogardus, Margaret, Villalona-Calero, Miguel, Diaz, Zuanel, Day, Roger, Eisenberg, Marcia, Anderson, Steven M, Puzanov, Igor, Galluzzi, Lorenzo, Gardner, Mark, Ernstoff, Marc S

“…Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients respond, and current biomarkers including PD-L1…”
Get full text

Safety of neoadjuvant chemotherapy in patients with muscle‐invasive bladder cancer and malignant ureteric obstruction by Strother, Marshall C., Kutikov, Alexander, Epstein, Matthew, Bochner, Emily, Deng, Mengying, Handorf, Elizabeth, Lewis, Bianca, Ghatalia, Pooja, Greenberg, Richard E., Chen, David, Viterbo, Rosalia, Anari, Fern, Smaldone, Marc C., Zibelman, Matthew R., Uzzo, Robert G., Plimack, Elizabeth R., Geynisman, Daniel M.

“…Objectives To determine whether patients with carcinoma invading bladder muscle (MIBC) and ureteric obstruction can safely receive cisplatin‐based neoadjuvant…”
Get full text

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer by Zarrabi, Kevin K., Narayan, Vivek, Mille, Patrick J., Zibelman, Matthew R., Miron, Benjamin, Bashir, Babar, Kelly, William Kevin

“…Prostate cancer is the most common cancer among men and the second leading cause of cancer-related deaths in men in the United States. The treatment paradigm…”
Get full text

Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus (SAGE): Results of a Phase II Trial by Geynisman, Daniel M, Kadow, Brian T, Shuch, Brian M, Boorjian, Stephen A, Matin, Surena F, Rampersaud, Edward, Milestone, Barton N, Plimack, Elizabeth R, Zibelman, Matthew R, Kutikov, Alexander, Smaldone, Marc C, Chen, David Yt, Viterbo, Rosalia, Joshi, Shreyas, Greenberg, Richard E, Malizzia, Lois, McGowan, Thomas, Ross, Eric A, Uzzo, Robert G

“…Everolimus decreases tumor volume of renal angiomyolipomas in patients with tuberous sclerosis. No prospective data are available regarding the effect of…”
Get full text

Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer by Miron, Benjamin, Hoffman-Censits, Jean H., Anari, Fern, O’Neill, John, Geynisman, Daniel M., Zibelman, Matthew R., Kutikov, Alexander, Viterbo, Rosalia, Greenberg, Richard E., Chen, David, Lallas, Costas D., Trabulsi, Edouard J., Alpaugh, R. Katherine, Dulaimi, Essel, Golemis, Erica A., Uzzo, Robert, Ross, Eric A., Plimack, Elizabeth R.

“…Cisplatin-based neoadjuvant chemotherapy (NAC) has demonstrated an overall survival (OS) benefit in muscle-invasive bladder cancer (MIBC). However, only a…”
Get full text

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients by Pabla, Sarabjot, Conroy, Jeffrey M, Nesline, Mary K, Glenn, Sean T, Papanicolau-Sengos, Antonios, Burgher, Blake, Hagen, Jacob, Giamo, Vincent, Andreas, Jonathan, Lenzo, Felicia L, Yirong, Wang, Dy, Grace K, Yau, Edwin, Early, Amy, Chen, Hongbin, Bshara, Wiam, Madden, Katherine G, Shirai, Keisuke, Dragnev, Konstantin, Tafe, Laura J, Marin, Daniele, Zhu, Jason, Clarke, Jeff, Labriola, Matthew, McCall, Shannon, Zhang, Tian, Zibelman, Matthew, Ghatalia, Pooja, Araujo-Fernandez, Isabel, Singavi, Arun, George, Ben, MacKinnon, Andrew Craig, Thompson, Jonathan, Singh, Rajbir, Jacob, Robin, Dressler, Lynn, Steciuk, Mark, Binns, Oliver, Kasuganti, Deepa, Shah, Neel, Ernstoff, Marc, Odunsi, Kunle, Kurzrock, Razelle, Gardner, Mark, Galluzzi, Lorenzo, Morrison, Carl

“…Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience…”
Get full text

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors by Conroy, Jeffrey M, Pabla, Sarabjot, Nesline, Mary K, Glenn, Sean T, Papanicolau-Sengos, Antonios, Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Wang, Yirong, Lenzo, Felicia L, Bshara, Wiam, Khalil, Maya, Dy, Grace K, Madden, Katherine G, Shirai, Keisuke, Dragnev, Konstantin, Tafe, Laura J, Zhu, Jason, Labriola, Matthew, Marin, Daniele, McCall, Shannon J, Clarke, Jeffrey, George, Daniel J, Zhang, Tian, Zibelman, Matthew, Ghatalia, Pooja, Araujo-Fernandez, Isabel, de la Cruz-Merino, Luis, Singavi, Arun, George, Ben, MacKinnon, Alexander C, Thompson, Jonathan, Singh, Rajbir, Jacob, Robin, Kasuganti, Deepa, Shah, Neel, Day, Roger, Galluzzi, Lorenzo, Gardner, Mark, Morrison, Carl

“…PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at…”
Get full text